SCHEMBL16070604

SCHEMBL16070604

C#Cc1ccc([C@H](O)C(C)O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.37
ADRA2C P18825 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ADRA2A P08913 1/20 0.34
LMNA P02545 1/20 0.34
HIF1A Q16665 1/20 0.34
AOC3 Q16853 1/20 0.34
CYP2C9 P11712 2/20 0.34
ALDH1A1 P00352 2/20 0.33
APLNR P35414 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
PTPN1 P18031 1/20 0.32
CHRM2 P08172 1/20 0.32
ADRA1A P35348 1/20 0.32
RGS12 O14924 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16070609 1.00 HDAC8 (0.37) HDAC8ADRA2CKDM4EADRA2ALMNA
SCHEMBL16070696 1.00 HDAC8 (0.37) HDAC8ADRA2CKDM4EADRA2ALMNA
SCHEMBL17894156 0.83 HDAC8 (0.37) HDAC8CYP2C9CA12CA1CA2
SCHEMBL19435390 0.83 HDAC8 (0.37) HDAC8CYP2C9CA12CA1CA2
SCHEMBL30846910 0.82 NOS3 (0.41) HDAC8CYP2C9ALDH1A1CA12CA1
SCHEMBL16070644 0.82 NOS3 (0.41) HDAC8CYP2C9ALDH1A1CA12CA1
SCHEMBL16070587 0.82 NOS3 (0.41) HDAC8CYP2C9ALDH1A1CA12CA1
SCHEMBL13832177 0.77 HDAC8 (0.40) HDAC8CYP2C9CA12CA1CA2
SCHEMBL624888 0.77 PYCR1 (0.42) HDAC8LMNAHIF1ACYP2C9CA12
SCHEMBL28321091 0.77 ESR1 (0.46) HDAC8CYP2C9CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2975022-B1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF FUJIFILM TOYAMA CHEMICAL CO LTD (JP) 2019-05-08 EP disclosed
US-9862676-B2 Hydroxamic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2018-01-09 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
EP-2975022-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2016-01-20 EP disclosed
WO-2014142298-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF 富山化学工業株式会社 (JP) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF H1-0, H1-2, HDAC1 HDAC8 30/4885ADRA2C 4514/4885KDM4E 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.